Skip to content
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

Get the podcast

Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h

The Audio Journal of Oncology
Bengt Eriksson

Bengt Eriksson

REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, AtlantaBENGT ERIKSSON, Gothenburg UniversityIn a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more fromBengt Erikssonof Gothenburg University.

Tags

annual meetinganticoagulantsanticoagulationashbengt erikssonbloodblood clotclotenoxaparingothenburg universityhematologichip replacementpatientpodcastpodcastingpreventionrisktrial

More from ASH 2007

All 11 interviews

This is the last of the 11 ASH 2007 interviews. See them all.

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism

ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (V

26 Jan 2018
10 min